Innocrin Receives $28,000,000 Series D Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=69d2d758-d4ad-4b63-96b4-0f9a577e7853
Date
4/16/2015
Company Name
Innocrin
Mailing Address
4505 Emperor Boulevard Durham, NC 27703 USA
Company Description
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC).
Website
http://www.innocrinpharma.com
Transaction Type
Venture Equity
Transaction Amount
$28,000,000
Transaction Round
Series D
Proceeds Purposes
Innocrin plans to use the proceeds to accelerate parallel Phase 2 CRPC program studies that are being led by the Memorial Sloan Kettering Cancer Center (MSK) and the NCI.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor